News/ News/ Sales and Marketing J&J’s Tremfya to join crowded psoriatic arthritis market after FDA okay Richard Staines AbbVie, Eli Lilly, Johnson & Johnson, Pfizer, psoriatic arthritis, Sun Pharma, Tremfya 0 Comment The FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23 Share X J&J’s Tremfya to join crowded psoriatic arthritis market after FDA okay https://pharmaphorum.com/news/fda-approves-jjs-tremfya-in-psoriatic-arthritis/